Cymbalta Eli Lilly and Company - Treatment for Depression

Cymbalta, a balanced and potent reuptake inhibitor of serotonin and norepinephrine, is a new option for treating the broad range of emotional and physical symptoms of depression.

Related Articles:

FDA Approves Cymbalta for Maintenance Treatment of Major Depressive Disorder - November 30, 2007

FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder - February 26, 2007

FDA Extends Action Date for Cymbalta for Continued Analysis of Already-Submitted Data - June 24, 2004

Latest FDA Drug Approvals...

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Oct | Dec

Daily MedNews
Pharma Industry News
New Drug Applications
New Drug Approvals
Clinical Trial Results
Generic Drug Approvals